Oxybutynin Chloride in Managing Hot Flashes

• ClinicalTrials.gov Identifier: NCT02961790
• Recruitment Status: Completed
• First Posted: November 11, 2016
• Results First Posted: June 3, 2019
• Last Update Posted: January 18, 2020
• Sponsor: Academic and Community Cancer Research United
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): Academic and Community Cancer Research United

Study Description

Brief Summary:

This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy. Previous studies have shown that oxybutynin is effective in managing hot flashes, however doses used in prior studies have resulted in side effects. This trial is evaluating lower doses of oxybutynin with the goal of determining if they are efficacious with less side effects.

ADAM-VTE

Condition or disease	Intervention/treatment	Phase
Breast Carcinoma; Ductal Breast Carcinoma In Situ; Hot Flashes; Lobular Breast Carcinoma In Situ; No Evidence of Disease	Drug: Oxybutynin Chloride; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration	Phase 3

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine whether oxybutynin chloride (oxybutynin) can diminish hot-flash activity in women with a history of breast cancer or in women who have a concern about taking estrogen for fear of breast cancer.

SECONDARY OBJECTIVES:

I. To perform a dose-response evaluation of two oxybutynin doses. II. To determine the toxicity of oxybutynin in the study population. III. To assess the impact of hot-flash activity on overall quality of life and to examine whether oxybutynin can diminish this impact on quality of life.

OUTLINE: Patients are randomized into 1 of 4 groups.

GROUP I (LOW-DOSE OXUBUTYNIN CHLORIDE): Patients receive lower dose oxybutynin chloride orally (PO) twice a day (BID) on days 8-49 in the absence of unacceptable toxicity.

GROUP II (LOW-DOSE PLACEBO): Patients receive lower dose placebo PO BID on days 8-49 in the absence of unacceptable toxicity.

GROUP III (HIGH-DOSE OXUBUTYNIN CHLORIDE): Patients receive lower dose oxybutynin chloride PO BID on days 8-14 and higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.

GROUP IV (HIGH-DOSE PLACEBO): Patients receive lower dose placebo PO BID on days 8-14 and higher dose placebo on days 15-49 in the absence of unacceptable toxicity.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 150 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Supportive Care
• Official Title: A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes
• Actual Study Start Date: December 9, 2016
• Actual Primary Completion Date: April 27, 2018
• Actual Study Completion Date: April 27, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: Group I (low-dose oxybutynin chloride); Patients receive lower dose oxybutynin chloride PO BID on days 8-49 in the absence of unacceptable toxicity.	Drug: Oxybutynin Chloride; Given PO; Other Names: Ditropan; Gelnique; MJ-4309-1; Oxybutynin Hydrochloride; Other: Quality-of-Life Assessment; Ancillary studies; Other Name: Quality of Life Assessment; Other: Questionnaire Administration; Ancillary studies
Placebo Comparator: Group II (low-dose placebo); Patients receive lower dose placebo PO BID on days 8-49 in the absence of unacceptable toxicity.	Other: Placebo; Given PO; Other Names: placebo therapy; PLCB; sham therapy; Other: Quality-of-Life Assessment; Ancillary studies; Other Name: Quality of Life Assessment; Other: Questionnaire Administration; Ancillary studies
Experimental: Group III (high-dose oxybutynin chloride); Patients receive lower dose oxybutynin chloride PO BID on days 8-14 and higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.	Drug: Oxybutynin Chloride; Given PO; Other Names: Ditropan; Gelnique; MJ-4309-1; Oxybutynin Hydrochloride; Other: Quality-of-Life Assessment; Ancillary studies; Other Name: Quality of Life Assessment; Other: Questionnaire Administration; Ancillary studies
Placebo Comparator: Group IV (high-dose placebo); Patients receive lower dose placebo PO BID on days 8-14 and higher dose placebo on days 15-49 in the absence of unacceptable toxicity.	Other: Placebo; Given PO; Other Names: placebo therapy; PLCB; sham therapy; Other: Quality-of-Life Assessment; Ancillary studies; Other Name: Quality of Life Assessment; Other: Questionnaire Administration; Ancillary studies

Outcome Measures

Primary Outcome Measures :

1. Average Change in Hot Flash Activity Score From Baseline to Week 7 for Low Dose Oxybutynin vs Placebo and for High Dose Oxybutynin vs Placebo [ Time Frame: Baseline up to day 49 ]
   Average change in hot flash activity score from baseline to Week 7 for Low Dose Oxybutynin vs Placebo. The hot flash activity will be measured by the weekly average hot flash score (Sloan JA, et. al., 2001), which is a composite entity of both frequency and severity of hot flashes (The Hot Flash Diary collects the following information for Day 1- Day 7 of each week: Number of mild hot flashes, Number of moderate hot flashes, Number of severe hot flashes, Number of very severe hot flashes). This is a count, so it can range from 0 to infinity.

Secondary Outcome Measures :

1. Average Change in Hot Flash Score From Week 1 to Week 7 Comparing Low Dose Oxybutynin to Placebo [ Time Frame: Baseline up to day 49 ]
   Average change in Hot Flash Score from Week 1 to Week 7 Comparing Low Dose Oxybutynin to Placebo. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included low dose oxybutynin, weeks 1-7, no current aromatase inhibitor, age group 18-49, no tamoxifen, hot flash symptom duration < 9 months, and 4-9 hot flashes/day as fixed effects, and participant and error as random effects. The mean change in Hot Flash Score from Week 1 to Week 7 is reported below for the low-dose oxybutynin and placebo groups.
2. Average Change in Hot Flash Score From Week 1 to Week 7 Comparing High Dose Oxybutynin to Placebo [ Time Frame: Baseline up to day 49 ]
   Average change in Hot Flash Score from Week 1 to Week 7 Comparing High Dose Oxybutynin to Placebo. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included low dose oxybutynin, weeks 1-7, no current aromatase inhibitor, age group 18-49, no tamoxifen, hot flash symptom duration < 9 months, and 4-9 hot flashes/day as fixed effects, and participant and error as random effects. The mean change in Hot Flash Score from Week 1 to Week 7 is reported below for the high-dose oxybutynin and placebo groups.
3. Average Change of Severity of Stomach Pain/Cramps Symptoms as Measured by the Symptom Experience Questionnaire From Baseline to Week 7 for Low Dose Oxybutynin vs Placebo and for High Dose Oxybutynin vs Placebo [ Time Frame: Baseline up to day 49 ]
   Average Change of severity of Stomach pain/cramps symptoms as measured by the Symptom Experience Questionnaire From Baseline to Week 7 for Low Dose Oxybutynin vs Placebo and for High Dose Oxybutynin vs Placebo The Symptom Experience Questionnaire stomach pain/cramps item ("Over the past week, have you experienced stomach pain or cramps?") is scored from 0 to 10 with higher values being worse symptoms. So a negative value means the symptom is improving and a positive score means the symptom is getting worse.
4. Average Change of Daily Interference (Work) From Baseline to Week 7 as Measured by the Hot Flash-Related Daily Interference Scale (HFRDIS) Comparing Low Dose Oxybutynin vs Placebo and High Dose Oxybutynin vs Placebo [ Time Frame: Baseline up to day 49 ]
   Average Change of daily interference (Work) from baseline to Week 7 as measured by the Hot Flash-Related Daily Interference Scale (HFRDIS) comparing Low dose oxybutynin vs Placebo and High dose oxybutynin vs Placebo. HFRDIS Work item ("Work (work outside the home and housework)") Interference scores run from 0 to 10 with 0 being no interference and 10 being complete interference.
5. Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4) [ Time Frame: Up to 7 weeks ]
   The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns within patient groups. In addition, we will review all adverse event data that is graded as 3, 4, or 5 and classified as either "unrelated" or "unlikely to be related" to study treatment in the event of an actual relationship developing. The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• History of breast cancer, ductal breast carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS) (currently without evidence of malignant disease) OR a concern about taking estrogen for fear of breast cancer
• Bothersome hot flashes (defined by their occurrence of >= 28 times per week and of sufficient severity to prompt the patient to seek therapeutic intervention)
• Presence of hot flashes for > 30 days prior to study entry
• Ability to complete questionnaire(s) by themselves or with assistance
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 0, 1
• Ability to provide informed written consent
• Life expectancy >= 6 months
• Willing to work with the enrolling institution for follow-up (during the active monitoring phase of the study)

Exclusion Criteria:

• Any of the following current (=< 4 weeks prior) or planned therapies:

  • Antineoplastic chemotherapy (anti-HER2 agents allowed)
  • Androgens
  • Estrogens (any delivery route)
  • Progestogens
  • Tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have been on a constant dose for at least 28 days and must not be expected to stop the medication during the study period
  • Selective serotonin reuptake inhibitors (SSRIs)/serotonin?norepinephrine reuptake inhibitors (SNRIs), when being used for hot flash management or other indications such as depression, is allowed, assuming the dose will remain unchanged for the study duration
  • Gabapentin/pregabalin, when being used for hot flash management (use for other indications, such as pain, is allowed, assuming the dose will remain unchanged for the study duration)
  • Clonidine
  • Agents with known potent anticholinergic activity; agents with mild-moderate anticholinergic activity are allowed
• Prior use of oxybutynin during the period in which patient has had hot flashes
• Pregnant women
• Nursing women

• History of any of the following contraindications to oxybutynin:

  • Uncontrolled gastroesophageal reflux disease (GERD) despite appropriate therapy; if patient has history of GERD, but symptoms are well-controlled with medical treatment, patient is eligible
  • Ulcerative colitis
  • Narrow-angle glaucoma
  • Urinary retention
  • Hypersensitivity to oxybutynin or any other components of the product
  • Current uncontrolled hyperthyroidism
  • Coronary heart disease (angina or prior myocardial infarction)
  • Congestive heart failure
  • Symptomatic cardiac arrhythmias
  • Current uncontrolled hypertension
  • Myasthenia gravis
  • Dementia

Contacts and Locations

Locations

United States, Illinois

Illinois CancerCare-Peoria

Peoria, Illinois, United States, 61615

Carle Cancer Center NCI Community Oncology Research Program

Urbana, Illinois, United States, 61801

United States, Iowa

Oncology Associates at Mercy Medical Center

Cedar Rapids, Iowa, United States, 52403

United States, Kansas

Cancer Center of Kansas - Wichita

Wichita, Kansas, United States, 67214

United States, Kentucky

Saint Elizabeth Medical Center South

Edgewood, Kentucky, United States, 41017

United States, Michigan

Michigan Cancer Research Consortium NCORP

Ann Arbor, Michigan, United States, 48106

United States, Minnesota

Mayo Clinic

Rochester, Minnesota, United States, 55905

United States, North Carolina

Waverly Hematology Oncology

Cary, North Carolina, United States, 27518

United States, South Carolina

AnMed Health Cancer Center

Anderson, South Carolina, United States, 29621

United States, South Dakota

Rapid City Regional Hospital

Rapid City, South Dakota, United States, 57701

United States, Wisconsin

Saint Vincent Hospital -Green Bay

Green Bay, Wisconsin, United States, 54301

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States, 53792

Marshfield Clinic

Marshfield, Wisconsin, United States, 54449

Sponsors and Collaborators

Academic and Community Cancer Research United

National Cancer Institute (NCI)

Investigators

• Principal Investigator: Charles Loprinzi; Academic and Community Cancer Research United

  Study Documents (Full-Text)

Documents provided by Academic and Community Cancer Research United:

Study Protocol and Statistical Analysis Plan  [PDF] September 8, 2017

More Information

• Responsible Party: Academic and Community Cancer Research United
• ClinicalTrials.gov Identifier: NCT02961790
• Other Study ID Numbers: ACCRU-SC-1603; NCI-2016-01603 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); ACCRU-SC-1603 ( Other Identifier: Academic and Community Cancer Research United ); P30CA015083 ( U.S. NIH Grant/Contract )
• First Posted: November 11, 2016
• Results First Posted: June 3, 2019
• Last Update Posted: January 18, 2020
• Last Verified: August 2018

Additional relevant MeSH terms:

Carcinoma; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Breast Carcinoma In Situ; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Hot Flashes; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Breast Diseases; Skin Diseases; Carcinoma, Ductal; Adenocarcinoma; Neoplasms, Ductal, Lobular, and Medullary; Mandelic Acids; Oxybutynin; Parasympatholytics; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Urological Agents; Anti-Infective Agents, Urinary